CHAPTER 1 EXECUTIVE SUMMARY
- Key findings
- Strategic outlook
- Current positioning: competitive outlook 2004
- Datamonitors strategic recommendations
- Key issues facing King Pharmaceuticals: 2005-10
- King Pharmaceuticals forecast revenue stream, 2005-10
CHAPTER 2 GLOBAL COMPANY STRATEGY
- Introduction to King Pharmaceuticals
- Assessment of strategic position
- Strengths
- Weaknesses
- Opportunities
- Threats
- Datamonitors strategic recommendations
- Therapeutic foci
- Growth strategy assessment
- Organic growth
- Partnerships/licensing
- Mergers and acquisitions
- Mylans failed acquisition
- Corporate alliances and deals
- Elan
- Palatin Technologies
- Novavax
- Salix Pharmaceuticals
CHAPTER 3 GLOBAL PORTFOLIO AND PIPELINE ANALYSIS
- Evolution of therapy area focus, 2004-10
- Key growth drivers/resistors
- Cardiovascular franchise
- Marketed products
- Altace (ramipril)
- Thrombin-JMI (thrombin)
- Adenoscan (adenosine) and Adenocard (adenosine)
- R&D compounds
- Cardiovascular portfolio sales forecasts and forecast revenue growth
- CNS franchise
- Marketed products
- Skelaxin (metaxalone)
- Sonata (zaleplon)
- R&D compounds
- CNS portfolio sales forecasts and forecast revenue growth
- Diabetes and endocrinology franchise
- Marketed products
- Levoxyl (levothyroxine sodium)
- Cytomel/Triostat (liothyronine)
- R&D compounds
- Diabetes and Endocrinology portfolio sales forecasts and forecast revenue growth
- Infectious disease franchise
- Marketed products
- Bicillin (penicillin G benzathine)
- Synercid (quinupristin/dalfopristin)
- R&D compounds
- Infectious disease portfolio sales forecasts and forecast revenue growth
- Other products
- Marketed products
- Intal (sodium cromoglycate)
- Tilade (nedocromil sodium)
- R&D compounds
- Other products sales forecasts and forecast revenue growth
CHAPTER 4 CORPORATE DEVELOPMENT
- Financial position, 2003-04
- Financial position, 2003-04
- Profitability, 2000-04
- Revenue growth
- Cost structure
- Net Loss for 2004
- Liquidity, 2000-04
- 2004 performance benchmarking
- Business model clustering according to 2004 cost ratios
- 2004 growth and investment momentum
CHAPTER 5 APPENDIX : SUPPORTING DATA
- Financial data
- Exchange rates
- Methodology for therapy area forecasting
- List of Tables
- Table 1: Summary of Kings historical agreements, 2004-05
- Table 2: Breakdown of King Pharmaceuticals ethical sales by therapy area, 2004-10
- Table 3: Kings marketed cardiovascular portfolio
- Table 4: The leading US ACE inhibitor branded treatments for hypertension
- Table 5: Kings current cardiovascular R&D pipeline, 2004
- Table 6: Forecast sales for Kings cardiovascular portfolio, 2005-10
- Table 7: King Pharmaceuticals marketed CNS portfolio
- Table 8: King Pharmaceuticals CNS R&D pipeline, 2005
- Table 9: Forecast sales for Kings CNS portfolio, 2005-10
- Table 10: King Pharmaceuticals marketed diabetes and endocrinology portfolio
- Table 11: King Pharmaceuticals Diabetes and Endocrinology pipeline, 2005
- Table 12: Forecast sales for Kings diabetes and endocrinology portfolio, 2005-10
- Table 13: King Pharmaceuticals marketed infectious disease portfolio
- Table 14: King Pharmaceuticals infectious disease R&D pipeline, 2005
- Table 15: Forecast sales for Kings infectious disease portfolio, 2005-10
- Table 16: King Pharmaceuticals other marketed products
- Table 17: Kings current other R&D products
- Table 18: Forecast sales of King Pharmaceuticals other products portfolio, 2005-10
- Table 19: King Pharmaceuticals revenues by division, 2003-2004
- Table 20: King Pharmaceuticals expenses, 2003-2004
- Table 21: Exchange rates*, 2004
- List of Figures
- Figure 1: SWOT analysis for King Pharmaceuticals
- Figure 2: Competitive positioning of King Pharmaceuticals within the pharmaceutical market, 2004
- Figure 3: Forecast sales for King Pharmaceuticals major therapy areas, 2005-2010
- Figure 4: King Pharmaceuticals level of generic threat by therapy area to 2010
- Figure 5: Development of King Pharmaceuticals therapeutic strategy, 2005-10
- Figure 6: King Pharmaceuticals business development by therapy area
- Figure 7: King Pharmaceuticals ethical sales breakdown, 2004 and 2010 (forecast)
- Figure 8: King Pharmaceuticals growth drivers and resistors, 2005-10
- Figure 9: King Pharmaceuticals profitability stream, 2000-2004
- Figure 10: Kings liquid assets versus total liabilities, 2000-2004
- Figure 11: R&D and S,G&A spend and COGS as a proportion of sales, 2004
- Figure 12: Benchmarking of financial strength, 2004
|
Related Report
|
View Cart
